Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554890 · ClinicalTrials.gov registry record · Phase 4
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 887
- Enrollment target
NCT02554890: Completed Phase 4 study, sponsored by Novartis Pharmaceuticals.
NCT02554890 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 887 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02554890, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 887 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).
Primary Outcome
To assess the effect of in-hospital initiation of sacubitril/valsartan vs. enalapril on the time-averaged percentage change of NT-proBNP from baseline in patients who have been stabilized following hospitalization for ADHF and reduced ejection fraction (left ventricular ejection fraction \[LVEF\] ≤ 40%) between week 4 and 8. Number of patients with both a baseline value and a value at Week 4 or Week 8. Plasma NT-proBNP (pg/mL) values were averaged from Week 4 and Week 8 visits. N-terminal pro b
Interventions
- DRUG Enalapril
- DRUG sacubitril/valsartan (LCZ696)
- DRUG sacubitril/valsartan (LCZ696) matching placebo
- DRUG enalapril matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 887 participants |
| Start Date | 2016-04-29 |
| Est. Completion | 2018-07-24 |
| Phase | Phase 4 |
What the finished NCT02554890 record still lists
NCT02554890 is an interventional study that assigns participants to a tested intervention. The registered 887 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% higher).
The record links to 0 conditions, and to 4 interventions - of which Enalapril is the first listed.
NCT02554890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02554890 about?
NCT02554890 is a clinical study titled "Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.". The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejecti...
What is the current status of trial NCT02554890?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 887 participants. The study started on 2016-04-29. Estimated completion is 2018-07-24.
What interventions are being tested in trial NCT02554890?
The interventions under investigation include: Enalapril (DRUG), sacubitril/valsartan (LCZ696) (DRUG), sacubitril/valsartan (LCZ696) matching placebo (DRUG), enalapril matching placebo (DRUG).
Who is sponsoring clinical trial NCT02554890?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02554890's enrollment target sits among peer trials
887 87th of 2000 higher than 1,914 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI